Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021
01 Noviembre 2021 - 2:30PM
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:
ZIOP), today announced that it will report financial results for
the third quarter ended September 30, 2021 on Monday, November 8,
2021, after the close of U.S. markets. Following the announcement,
the Company will host a conference call and webcast at 4:30 p.m. ET
to provide a corporate update and review the financial results.
The conference call can be accessed by dialing
877-451-6152 (United States) or 201-389-0879 (International) with
the conference code 13724384. A live webcast may be accessed using
the link here, or by visiting the “Investors” section of the
Ziopharm website at www.ziopharm.com. After the live webcast, the
event will be archived on Ziopharm’s website for approximately 90
days after the call.
About Ziopharm Oncology,
Inc.Ziopharm is a clinical-stage oncology-focused cell
therapy company, developing T-cell receptor (TCR) therapies based
on its non-viral Sleeping Beauty gene transfer platform and its
unique cancer hotspot Library, covering common tumor-related
mutations in key oncolytic genes such as KRAS and TP53. The Company
has clinical and strategic collaborations with the National Cancer
Institute and The University of Texas MD Anderson Cancer Center.
For more information, please visit www.ziopharm.com.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about ZIOPHARM Oncology Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias